|
SALL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.626032641866E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.04041253179821E-14 |
| Normal-vs-Stage2 |
9.721800E-03 |
| Normal-vs-Stage3 |
1.95119476131822E-11 |
| Normal-vs-Stage4 |
2.40141240226421E-12 |
| Stage1-vs-Stage2 |
2.041800E-02 |
| Stage1-vs-Stage3 |
1.309840E-01 |
| Stage1-vs-Stage4 |
4.581600E-03 |
| Stage2-vs-Stage3 |
3.297200E-03 |
| Stage2-vs-Stage4 |
3.593000E-04 |
| Stage3-vs-Stage4 |
2.090200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
9.50739999999728E-05 |
| Normal-vs-Asian |
3.01979999894897E-08 |
| Caucasian-vs-AfricanAmerican |
3.466800E-01 |
| Caucasian-vs-Asian |
5.054400E-01 |
| AfricanAmerican-vs-Asian |
6.606800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.27389998549887E-09 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
6.287800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64557256709941E-12 |
| Normal-vs-Age(41-60Yrs) |
7.71850028336019E-10 |
| Normal-vs-Age(61-80Yrs) |
2.23789875519742E-11 |
| Normal-vs-Age(81-100Yrs) |
2.004900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.972300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.790200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.713200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.903400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.319000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.529600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.78700000247534E-08 |
| Classical-VS-Follicular |
5.305600E-02 |
| Classical-VS-Other |
5.587800E-01 |
| Classical-VS-Normal |
1.66144875635155E-12 |
| Tall-VS-Follicular |
1.30520000363177E-08 |
| Tall-VS-Other |
2.444000E-01 |
| Tall-VS-Normal |
1.62503344114384E-12 |
| Follicular-VS-Other |
2.789600E-01 |
| Follicular-VS-Normal |
2.07740000002232E-06 |
| Other-VS-Normal |
2.280900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.55420001710394E-09 |
| Normal-vs-N1 |
6.66133814775094E-16 |
| N0-vs-N1 |
2.02750038980071E-10 |
|
|
